TAK-915 is a potent, selective, brain-penetrant and orally active phosphodiesterase 2A (PDE2A) inhibitor with an IC 50 of 0.61 nM. TAK-915 is >4100-fold more selectivity for PDE2A than PDE1A. TAK-915 has the potential for neuropsychiatric and neurodegenerative disorders treatment In Vivo TAK-915 (3 mg/kg; oral administration; daily; for 4 days; male F344 rats) treatment significantly reduces escape latency in aged rats in the Morris water maze task. TAK-915 (1, 3, and 10 mg/kg, p.o.) dose-dependently attenuates the non-selective muscarinic antagonist scopolamine-induced memory deficits in rats. Oral dosing of TAK-915 (compound 36) (3 or 10 mg/kg) in mice produces a dose-dependent increase in 3',5'-cyclic guanosine monophosphate (cGMP) levels, with significant cGMP increases observed at a dose of 10 mg/kg . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male F344 rats (10-week-old and 26-month-old) bearing morris water maze taskDosage: 3 mg/kg Administration: Oral administration; daily; for 4 days Result: Significantly reduced escape latency in aged rats in the Morris water maze task. Form:Solid IC50& Target:PDE2A 0.61 nM (IC 50 ) PDE1A 2497 nM (IC 50 )